In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19. The case explores how a company builds a digital organization, and leverages artificial intelligence and other digital resources to speed its operations, manage its processes and ensure quality across research, testing and manufacturing.
Built from the ground up as such a digital organization, Moderna was able to respond to the challenge of developing a vaccine as soon as the gene sequence for the virus was posted to the Web on January 11, 2020. As the vaccine enters Phase III clinical trials, Bancel considers several issues: How should Bancel and his team balance the demands of developing a vaccine for a virus creating a global pandemic alongside the other important vaccines and therapies in Moderna’s pipeline? How should Moderna communicate its goals and vision to investors in this unprecedented time? Should Moderna be concerned it will be pegged as “a COVID-19 company?”
Built from the ground up as such a digital organization, Moderna was able to respond to the challenge of developing a vaccine as soon as the gene sequence for the virus was posted to the Web on January 11, 2020. As the vaccine enters Phase III clinical trials, Bancel considers several issues: How should Bancel and his team balance the demands of developing a vaccine for a virus creating a global pandemic alongside the other important vaccines and therapies in Moderna’s pipeline? How should Moderna communicate its goals and vision to investors in this unprecedented time? Should Moderna be concerned it will be pegged as “a COVID-19 company?”
Keywords: COVID-19; vaccine; digital organizations; Organizational Structure; Operations; Management; Health Pandemics; Research and Development; Goals and Objectives;
Citation:
Iansiti, Marco, Karim R. Lakhani, Hannah Mayer, and Kerry Herman. "Moderna (A)." Harvard Business School Case 621-032, September 2020. (Revised October 2020.) View Details